S&P 500 Healthcare Sector SEC Filings — October 27, 2026

Nine-month adjusted diluted EPS rose to $6.45 from $3.26 and GAAP net earnings reversed to $2,561 Million from a $(5,573) Million loss; Q3 adjusted EPS of $0.58 vs $0.50 a year earlier

Long-term debt cut to $15,454 Million from $17,351 Million at 12/31/2025 with $1,872 Million of 9M 2026 repayments and repurchases, strengthening the balance sheet

2026 GAAP diluted EPS guidance floor raised to greater than $3.46 and adjusted floor to greater than $5.20

Operating cash flow was negative at $(3,669) Million, a major cash conversion warning despite earnings recovery

Commercial premium revenue fell 21% YoY and at-risk membership dropped from 27.97 million to 25.70 million, with Medicare and PDP growth only partly offsetting

Premium tax expense growth outpaced premium and service revenue growth, compressing the revenue-quality picture even as total revenues rose 6% YoY

HBR guidance range lowered to 90.4%-91.1%, signaling medical cost pressure that partly offsets the EPS floor raise

Former Yum! Brands CEO David W. Gibbs joined the board, adding digital transformation and customer-relationship experience to a 13-member board that is 12 independent

EVP and CRO Michael Feld sold 76 shares at $198.13 (~$15.1K) under a Rule 10b5-1 plan, leaving 19,568 shares; immaterial in size and pre-scheduled

BlackRock reports 30,382,653 shares (5.9%) as of 09/30/2026 with no single-person interest above 5%, a passive institutional holding without control intent

Operating cash flow of $(3,669) Million in the period is a material cash-generation deficit that the earnings recovery does not yet reflect

Commercial premium revenue down 21% YoY and total at-risk membership down from 27.97 million to 25.70 million (about -8%) signals franchise shrinkage in Marketplace

HBR guidance lowered to 90.4%-91.1%, a direct margin headwind that could cap the raised EPS floor

Premium tax expense growing faster than premium and service revenue erodes revenue quality and margin per member

Q3 GAAP loss of $(0.14) per share versus adjusted $0.58 shows a persistent gap between reported and adjusted results, with a prior-year $6.7 billion impairment still shaping the comparison

Q3 2026 operating loss of $(307) Million, though improved from $(6,954) Million, indicates the quarter remains loss-making on an operating basis

BlackRock's 5.9% stake with 29.76 million sole-voting shares adds to passive ownership concentration that can amplify index-driven flows

Nine-month adjusted EPS of $6.45 versus $3.26 with a raised 2026 adjusted floor above $5.20 may support multiple expansion if cash flow normalizes

$1,872 Million of 9M debt reduction and a $1.9 billion decline in long-term debt create room for further buybacks or refinancing savings

Medicare and PDP membership growth offsets commercial attrition, a mix shift toward a potentially more durable product line

Raised GAAP and adjusted EPS floors provide downside anchoring for the 2026 outlook if HBR pressure is contained

Board refresh with a commercially experienced director may strengthen launch execution oversight ahead of future product launches

A 5.9% long-term institutional holder with no control intent suggests a stable shareholder base during any turnaround

Centene's adjusted EPS roughly doubled on a nine-month basis while operating cash flow was $(3,669) Million, showing that accrual earnings and cash generation are diverging across the managed-care segment [implication: monitor cash conversion before extrapolating margin recovery]

Commercial/Marketplace attrition (-21% commercial premium, membership down ~8%) is being offset by Medicare and PDP growth, indicating a sector rotation toward government-sponsored lines [implication: government reimbursement rates and risk adjustment become the key earnings drivers]

Prior-year goodwill impairments of roughly $6.7 billion are distorting year-over-year comparisons; 2026 GAAP results are increasingly reflecting clean operations [implication: GAAP vs adjusted spreads should narrow over time]

Centene's $1.9 billion debt reduction alongside buybacks reflects balance-sheet repair as a capital allocation priority [implication: capital returns are likely to remain balance-sheet constrained near term]

The Amgen board addition of a former CEO with digital and customer-facing expertise points to a broader sector trend of recruiting commercial and operating talent onto healthcare boards [implication: operational execution is becoming a board-level differentiator]

Whether the $(3,669) Million cash outflow reverses in Q4 and full-year cash flow turns positive; next earnings release [date not provided in filings]

Whether medical cost ratio pressure worsens beyond the lowered 90.4%-91.1% range at the next quarterly update

Pace of Marketplace losses versus Medicare and PDP gains in upcoming enrollment disclosures

Any change to the greater-than-$3.46 GAAP and greater-than-$5.20 adjusted EPS floors in subsequent filings

First Audit and Compensation Committee actions involving the new director, and any launch-related commentary

Any further amended 13G filings signaling a move above the 5% threshold or change in voting control

Continued 10b5-1 sales by the Chief Revenue Officer to confirm whether this is routine or the start of a pattern